SOCS2 inhibits the tumorigenesis of GISTs and increases the sensitivity of GISTs to imatinib by suppression of KIT activation
Abstract The suppressors of cytokine signaling 2 (SOCS2) inhibits growth hormone receptor (GHR) signaling by negative feedback in the regulation of metabolism. In this study, we found that GHR upregulates SOCS2 expression, whereas KIT mutations, the key driver mutations of gastrointestinal stromal t...
Saved in:
Main Authors: | Liangying Zhang, Kun Xiao, Shaoting Zhang, Sien Zhao, Zimei Liu, Ming Wang, Kaiyue Qin, Yuanyuan Yu, Shujing Li, Lijun Ma, Jianmin Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-89477-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Secondary amyloidosis with concomitant gastric GIST and gastric adenocarcinoma - A case report
by: Ankita Soni, et al.
Published: (2023-07-01) -
Herbal Kit Application.
by: Muhwezi,Paul., et al.
Published: (2025) -
Transcriptome-proteome integration analysis identifies elevated expression of LARP7 promoting the tumorigenesis and development of gastrointestinal stromal tumors
by: Heng Zheng, et al.
Published: (2025-03-01) -
Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
by: Petra Belohlavkova, et al.
Published: (2024-09-01) -
Correction: Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability
by: Valerie Haller, et al.
Published: (2025-01-01)